Subscribe To

Price Alert Latest News Economic Calendar News

RPRX / Royalty Pharma raises FY2023 guidance after $475M Pfizer milestone payment

Royalty Pharma plc announced that it is raising its full year 2023 Adjusted Cash Receipts (non-GAAP) guidance to between $2.85 billion and $2.95 billion, up from $2.375 billion and $2.475 billion previously (excluding transactions announced subsequent to the date of this release), after receiving a $475 million accelerated milestone payment from Pfizer Inc (NYSE:PFE). The buyer of biopharmaceutical royalties said the Pfizer payment follows the US Food and Drug Administration (FDA) approval of Zavzpret (zavegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine. Read More

Demo Live Account See Partner Details

Content Topics

Royalty

Pharma

Raises

Fy2023

Guidance

After

475m

Pfizer

Milestone

Payment

Stock

RPRX

Posted: Mar 15 2023, 11:42

Author Name: Proactive Investors

RPRX News

By Zacks Investment Research
November 1, 2023

Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likel

By GlobeNewsWire
October 11, 2023

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial res

By Seeking Alpha
September 27, 2023

Royalty Pharma: The Time Has Come

Royalty Pharma offers a unique exposure in the pharmaceutical sector thanks to a diversified portfolio and lower operational risk vs. competitors. The

By Seeking Alpha
September 5, 2023

Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone

Q2 2023 earnings showcasted robust performance and raised forecast for 2023 non-GAAP adjusted cash receipts. Royalty Pharma enters strategic partnersh

By GlobeNewsWire
September 5, 2023

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming inve

By Zacks Investment Research
August 7, 2023

Why Royalty Pharma (RPRX) Might Surprise This Earnings Season

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

By Seeking Alpha
June 10, 2023

Royalty Pharma: A Strong Start To 2023 Bodes Well For The Future

Royalty Pharma acquires royalties on drugs in the commercial phase and the development phase. Thanks to a milestone payment, this year's cash receipts

By GlobeNewsWire
June 7, 2023

Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44t

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.